ORIC Latest Press Releases

-- November 6, 2026 --

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- November 3, 2026 --

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 4:01 PM

-- October 23, 2026 --

ORIC Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026 Globe Newswire 3:15 AM

ORIC Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial Globe Newswire 3:15 AM

-- October 19, 2026 --

ORIC Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 Globe Newswire 8:00 AM

-- October 5, 2026 --

ORIC Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development Globe Newswire 4:01 PM

-- October 2, 2026 --

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- September 4, 2026 --

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- September 2, 2026 --

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 4:05 PM

-- August 7, 2026 --

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- August 3, 2026 --

ORIC Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates Globe Newswire 4:05 PM

-- July 20, 2026 --

ORIC Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Globe Newswire 8:30 AM

-- July 14, 2026 --

ORIC Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA (Darolutamide), Supported by Clinical Collaboration with Bayer Globe Newswire 4:05 PM

-- July 2, 2026 --

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

Market Data Delayed 15 Minutes